Price
CHART BY
Frequently asked questions
What is VolitionRX's market capitalization?
The market capitalization of VolitionRX is $70.32M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for VolitionRX?
VolitionRX's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.267. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for VolitionRX's stock?
Currently, 5 analysts cover VolitionRX's stock, with a consensus target price of $3.125. Analyst ratings provide insights into the stock's expected performance.
What is VolitionRX's revenue over the trailing twelve months?
Over the trailing twelve months, VolitionRX reported a revenue of $1.31M.
What is the EBITDA for VolitionRX?
VolitionRX's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$22.87M. EBITDA measures the company's overall financial performance.
What is the free cash flow of VolitionRX?
VolitionRX has a free cash flow of -$21.72M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does VolitionRX have, and what sector and industry does it belong to?
VolitionRX employs approximately 85 people. It operates in the Health Care sector, specifically within the Medical Specialties industry.
What is the free float of VolitionRX's shares?
The free float of VolitionRX is 76.87M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $70.32M
- EPS (TTM)
- -$0.267
- Free Float
- 76.87M
- Revenue (TTM)
- $1.31M
- EBITDA (TTM)
- -$22.87M
- Free Cashflow (TTM)
- -$21.72M
Pricing
- 52W span
- $0.40$0.94
Analyst Ratings
The price target is $3.125 and the stock is covered by 5 analysts.
Buy
4
Hold
1
Sell
0
Information
VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.
- Employees
- 85
- Industries
- Medical Specialties
- Sector
- Health Care
Identifier
- ISIN
- US9286611077
- Primary Ticker
- VNRX
Fundamentals & EOD data from FactSet